CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
about
Toward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ RegimenLarge-Scale Off-Target Identification Using Fast and Accurate Dual Regularized One-Class Collaborative Filtering and Its Application to Drug RepurposingRepurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent.Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion currentMarketed nonsteroidal anti-inflammatory agents, antihypertensives, and human immunodeficiency virus protease inhibitors: as-yet-unused weapons of the oncologists' arsenal.Fluoxetine, an antidepressant, suppresses glioblastoma by evoking AMPAR-mediated calcium-dependent apoptosis.The role of interleukin-18 in glioblastoma pathology implies therapeutic potential of two old drugs-disulfiram and ritonavir.TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy.Itraconazole induces apoptosis and cell cycle arrest via inhibiting Hedgehog signaling in gastric cancer cells.Toward precision medicine in glioblastoma: the promise and the challenges.Anti-glioma Activity of Dapsone and Its Enhancement by Synthetic Chemical Modification.Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.Dual targeting of the thioredoxin and glutathione systems in cancer and HIV.Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report review of the literature.Novel Approaches to Apoptosis-Inducing Therapies.The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy.Agomelatine or ramelteon as treatment adjuncts in glioblastoma and other M1- or M2-expressing cancers.Repurposing itraconazole for the treatment of cancer.Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration-Approved Drugs.Targeting TCTP with Sertraline and Thioridazine in Cancer Treatment.Cell death-based treatment of childhood cancer.Drug Repurposing of Metabolic Agents in Malignant GliomaSertraline, chlorprothixene, and chlorpromazine characteristically interact with the REST-binding site of the corepressor mSin3, showing medulloblastoma cell growth inhibitory activities
P2860
Q26749972-7FDF6450-8905-4855-B046-4C17504D7E7EQ28554586-F7C8ACBE-8595-417E-8A7E-57EFE529AFBDQ34474583-1966B037-B605-4852-8279-51C2F627BAF2Q34957274-66A5AFD7-669D-4815-9F27-EA95763599A9Q35653603-B21D61B3-CF7C-467B-99E7-2F76A10D1FCBQ35741615-F528BE2B-9B29-4B9F-8CF4-2D126A0FBAE5Q36121190-1C9EAA0C-85D1-43C1-8E1B-81DF584CBCEFQ36546689-4040F200-9E14-492E-A43E-64799AF0C6DDQ37636690-4F76984A-488A-41F7-9D3F-8AF84B9B920AQ37747533-340B910E-BA9B-459B-896C-35264336CDBCQ38454659-CA3EA180-B85E-4B10-B9E4-8A32265A724EQ38602644-871561DF-D965-495C-B4F0-900F5B0BD016Q38816965-A9ACE137-3DCB-43C5-B833-514FB85AD2F4Q38823023-07E4F25E-9FCD-4908-8F35-E1AEDBB1E76AQ38926305-547C7D67-903B-4042-B901-A86D34E67289Q38936710-CC1DAEE4-1ECC-4A88-B7DB-DBF07ED44095Q41036251-985ADE9F-2499-48A4-A77E-35FB675AE6AFQ41103172-519C0A54-6101-46B9-98C7-B68697C62D4AQ41613808-388D5B6F-B68A-47F3-A16F-A94628980BE4Q42116442-A0187E0B-0979-4605-AA7E-DCD29DF5A6D2Q47214168-90182B95-6685-4D57-9764-4BF8569AFB9BQ49679684-F58BF925-C3B5-4F2D-8698-6B3753224556Q58738611-8CE5482B-8DBC-4BCA-BDFD-F11B716321CBQ58743854-97DACF93-8824-4186-9937-7D634306743C
P2860
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
CUSP9* treatment protocol for ...... tinuous low dose temozolomide.
@ast
CUSP9* treatment protocol for ...... tinuous low dose temozolomide.
@en
CUSP9* treatment protocol for ...... tinuous low dose temozolomide.
@nl
type
label
CUSP9* treatment protocol for ...... tinuous low dose temozolomide.
@ast
CUSP9* treatment protocol for ...... tinuous low dose temozolomide.
@en
CUSP9* treatment protocol for ...... tinuous low dose temozolomide.
@nl
prefLabel
CUSP9* treatment protocol for ...... tinuous low dose temozolomide.
@ast
CUSP9* treatment protocol for ...... tinuous low dose temozolomide.
@en
CUSP9* treatment protocol for ...... tinuous low dose temozolomide.
@nl
P2860
P356
P1433
P1476
CUSP9* treatment protocol for ...... tinuous low dose temozolomide.
@en
P2093
Richard E Kast
P2860
P304
P356
10.18632/ONCOTARGET.2408
P407
P577
2014-09-01T00:00:00Z